Diabetes is a "prothrombotic state" associated with accelerated atherosclerosis and inflammation (1) . Despite the proven benefits of aspirin therapy in the prevention of cardiovascular complications in the diabetic patient, the diabetic patient has a greater risk for thrombotic complications compared to non-diabetic patients (2) . It has been demonstrated that diabetic patients with acute coronary syndromes (ACS) are at higher risk for recurrent events compared to non-diabetic ACS patients (3) . Despite sharp declines in restenosis rates with the use of drug-eluting stents, diabetic patients with ACS remain at the highest risk for recurrent ischemia (4) . Moreover, recent studies have suggested that diabetes is an independent predictor of stent thrombosis and lower survival rates in patients treated with drug-eluting stents (5, 6) . It has been suggested that diabetic patients not treated with aspirin therapy generally display high platelet reactivity and elevated levels of platelet thromboxane synthesis, and that aspirin treatment in diabetic patients is less effective in inhibiting thromboxane synthesis compared to aspirin treatment in non-diabetic patients (7) . However, few studies have evaluated the efficacy of different aspirin doses in the diabetic patient in order to determine the optimal regimen. Currently, existing guidelines recommend low dose aspirin therapy in diabetic patients, however there is little evidence to support this recommendation (8) . In fact, in the primary prevention project (PPP), a higher cardiovascular risk was observed in diabetic patients on low dose aspirin compared to non-diabetic patients, indicating that the benefits of aspirin therapy may be outweighed by aspirin insensitive mechanisms of platelet activation (9) . In addition, long term treatment with high dose aspirin resulted in similar rates of death and cardiovascular events in diabetic and nondiabetic patients (10) . There are limited data quantifying the prevalence of platelet aspirin resistance in diabetic patients. In addition, no study has compared the effect of multiple aspirin doses on platelet function in both diabetic and non-diabetic patients using various methods. We hypothesized that diabetic patients with coronary artery disease during therapy with 81mg aspirin will exhibit a higher prevalence of aspirin resistance and higher platelet function than non-diabetic patients, and that higher aspirin doses will result in similar rates of resistance and similar levels of platelet function between groups. In this investigation we measured 11-dehydro-thromboxane B 2 in urine; conventional light transmittance aggregometry and two point-of-service analyzers.
Research Design and Methods
We studied 120 stable outpatients enrolled in the ASpirin-Induced Platelet EffeCT (ASPECT) study; a single-center, doubleblind, double crossover (Williams design) study evaluating the effect of 81, 162, and 325mg/day aspirin therapy in patients with coronary artery disease (11) . The study was approved by the Western Institutional Review Board (Olympia, WA) and all patients provided written informed consent prior to enrollment. Patients were randomly assigned to a drug treatment sequence of 81, 162, and 325mg/day for 4 weeks each over a 12 week period. Coronary artery disease was documented by coronary angiography or ultrafast computed tomography scan. Patients were older than 18 years of age. Patients were excluded from the study if they met any of the following criteria: bleeding diathesis or a history of gastrointestinal bleeding, hemorrhagic stroke, illicit drug or alcohol abuse, coagulopathy, major surgery within 6 weeks prior to randomization, platelet count <100,000/mm 3 , hematocrit <25%, creatinine >4mg/dL, or current use of nonsteroidal anti-inflammatory drugs, 
Light Transmittance Aggregometry
Platelet aggregation was assessed as described previously (12) . In brief, the blood-citrate tubes were centrifuged at 120g for 5 minutes to recover platelet rich plasma (PRP) and further centrifuged at 850g for 10 minutes to recover platelet poor plasma (PPP). The PRP and PPP were stored at room temperature to be used within 30 minutes. Platelets were stimulated with 5µM ADP, 2µg/mL collagen and 2 and 5mM AA. Aggregation was assessed using a Chronolog Lumi-Aggregometer (Model 490-4D) with the Aggrolink software package (Chronolog, Havertown, PA). Aggregation was expressed as the maximum percent change in light transmittance from baseline, using PPP as a reference.
VerifyNow™ Aspirin Assay
The VerifyNow™ is a turbidimetric based optical detection assay designed to measure platelet aggregation that is based upon the ability of activated platelets to bind to fibrinogen (13) . The cartridge contains a lyophilized preparation of human fibrinogen-coated beads, arachidonic acid, preservative and buffer. The fibrinogen-coated beads aggregate in whole blood in proportion to the number of unblocked platelet GPIIb/IIIa receptors. The instrument reports aggregation as aspirin reaction units (ARU).
Platelet Function Analyzer-100
® Assay
In the PFA-100 ® point-of-care assay platelets are exposed to high shear conditions within a cartridge containing a capillary, a sample reservoir, a collagen/epinephrine coated membrane and an aperture (14) . Epinephrine and collagen activate platelets in whole blood creating aggregate formation at the aperture, gradually diminishing and finally arresting blood flow. The PFA-100 ® records the time in seconds from the start of the test until the platelet aggregate occludes the aperture [closure time (CT)].
Aspirin Effect on Platelets of Diabetic Patients
Urinary 11-dh-TxB 2 The AspirinWorks ® enzyme-linked immunosorbent assay (ELISA) has been previously described (15) . In brief, assay buffer and urine was incubated with a monoclonal antibody followed by the addition of 11-dh-TxB 2 -alkaline phosphate tracer. Urinary 11-dh-TxB 2 concentrations were determined by measuring color development at 405nm using an ELISA reader and expressed as pg/mg creatinine.
Definitions Aspirin Resistance
Aspirin resistance was defined by previously reported criteria: ≥20% AA-, ≥70% ADP-and ≥70% collagen-induced aggregation by LTA (16); ≥550 ARU by VerifyNow™ (13); ≤193 seconds by PFA-100 ® (14); and upper quartile (>420) pg 11-dh-TxB 2 /mg creatinine during treatment with 81mg daily aspirin (17) .
Diabetes
Diabetes was present if at least one of the following criteria were present: a fasting glucose ≥126mg/dL, treatment with oral hypoglycemic agents, treatment with insulin (18) .
Statistical Analysis
Categorical variables are expressed as n (%) and continuous variables as mean ± SD. A one-way analysis of variance (ANOVA) for repeated measures was used to compare levels of platelet function between and within diabetic and nondiabetic patients. An unpaired t-test was used to compare the prevalence of aspirin resistance between groups; p<0.05 was considered significant. All statistical calculations were performed using SigmaStat software (Point Richmond, CA).
Results

Patients
One hundred twenty patients from the ASPECT study were analyzed with respect to diabetic status. Diabetes was observed in 30 patients (7 patients with type 1 diabetes and 23 patients with type 2 diabetes). Patient demographics are shown in Table 1 . The majority of patients were elderly, Caucasian men with a history of hyperlipidemia and hypertension receiving standard medical treatment for coronary artery disease, including statins, beta-blockers and angiotensin converting enzyme inhibitors. Diabetic patients had a higher prevalence of stroke and lower HDL levels compared to non-diabetic patients. Overall compliance with daily aspirin therapy was 98%.
AA-Induced Platelet Aggregation Measured by Light Transmittance Aggregometry
The effect of aspirin dose on AA-induced platelet aggregation between and within diabetic and non-diabetic patients is shown in Table 2 and Table 3 , respectively. AA-induced aggregation (2 and 5mM) was low in both patient groups and no significant effects of increased aspirin dosing on AA-induced platelet aggregation were observed between or within groups. Aspirin resistance was rare in both patient groups as measured by AA-induced aggregation. One diabetic patient was resistant by 2mM AA-induced LTA during treatment with 81mg and by 5mM AA-induced LTA during treatment with 81mg and 162mg. However, upon administration of 325mg aspirin no resistance was observed. Among the nondiabetic patients, one patient was resistant by 2mM AA-induced LTA while treated with 162mg and by 5mM AA-induced LTA during treatment with 81mg aspirin. Similar to the diabetic group, no resistance was observed during 325mg aspirin therapy.
Aspirin Effect on Platelets of Diabetic Patients
VerifyNow™ Aspirin Assay During treatment with 81mg and 162mg aspirin, ARU's were significantly higher in diabetic patients compared to nondiabetic patients (p=0.02 and p=0.04, respectively, Table 2 ). However, nearly identical ARU values were observed between groups during 325mg aspirin therapy (Table 2 ). In non-diabetic patients 162mg and 325mg aspirin provided significantly lower aggregation than 81mg aspirin (p=0.02 for both comparisons), whereas in diabetic patients only 325mg aspirin resulted in significantly lower aggregation than 81mg (p=0.004, Table  3 ).
A directional trend in reduced rates of aspirin resistance was observed in diabetic patients with doses greater than 81mg (p=0.16), however rates of resistance in non-diabetic patients were uninfluenced by increased aspirin dosing (Figure 1a) . Overall, diabetic patients during 81mg aspirin therapy displayed significantly greater rates of aspirin resistance than non-diabetic patients during 81mg aspirin therapy (p=0.04), with no differences observed between groups at 162mg or 325mg aspirin (Figure 1a) .
Urinary 11-dehydro-thromboxane B 2
During treatment with 81mg aspirin urinary 11-dehydro-thromboxane B 2 levels were significantly higher in diabetic patients compared to non-diabetic patients (p=0.02), whereas no significant differences were observed between groups during treatment with 162mg or 325mg aspirin (Table 2 ). Both 162mg and 325mg aspirin significantly reduced levels compared to 81mg aspirin in diabetic patients (p=0.01 and p=0.002, respectively), however a significant decrease in urinary thromboxane levels was not observed in non-diabetic patients with increased aspirin dosing (Table 3) .
A directional trend in reduced rates of aspirin resistance was observed in diabetic patients from 81mg to 162mg (p=0.24), whereas 325mg aspirin resulted in significantly decreased resistance rates compared to 81mg in diabetic patients (p=0.04, Figure 1b) . The prevalence of aspirin resistance was significantly lower in non-diabetic patients compared to diabetic patients at 81mg aspirin (p=0.02), and resistance rates were unaffected by increased aspirin dosing in non-diabetic patients (Figure 1b) .
ADP-Induced Platelet Aggregation
Measured by Light Transmittance Aggregometry ADP-induced platelet aggregation was significantly higher in diabetic patients compared to non-diabetic patients at both 81mg and 325mg aspirin therapy (p≤0.05 for both comparisons), however no significance was observed between groups at 162mg (p=0.20, Table 2 ). A dosedependent effect of aspirin on ADPinduced aggregation was not observed in either patient group (Table 3) . No significant differences in aspirin resistance rates were observed with increased aspirin dosing in diabetic patients (Figure 3 ). In contrast, 325mg aspirin significantly reduced resistance rates in non-diabetic patients (p=0.02) (Figure 2 ). Aspirin resistance rates were higher in diabetic patients compared to non-diabetic patients at all aspirin doses, however significance was observed between patient groups only at 325mg (p=0.002) (Figure 2 ).
Collagen-Induced Platelet Aggregation Measured by Light Transmittance Aggregometry
Collagen-induced platelet aggregation was significantly higher in diabetic patients compared to non-diabetic patients at 81mg aspirin (p<0.001), whereas no significant differences were observed between groups during treatment with 162mg or 325mg aspirin (Table 2 ). Both 162mg and 325mg aspirin significantly reduced collagen-
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induced platelet aggregation compared to 81mg aspirin in diabetic patients (p<0.001 for both comparisons), however a significant decrease in collagen-induced platelet aggregation was not observed in non-diabetic patients (Table 3) .
A significant decrease in aspirin resistance was observed in diabetic patients at doses greater than 81mg (p=0.01), however the prevalence of aspirin resistance was unaffected by aspirin dosing in nondiabetic patients (Figure 2 ). Aspirin resistance rates were significantly higher in diabetic patients compared to nondiabetic patients at 81mg (p<0.001), however similar rates of resistance were observed between groups at doses greater than 81mg (Figure 2 ).
Platelet Function Analyzer-100
® Assay A significant effect of aspirin dosing on mean closure time was not observed between patient groups as determined by PFA-100 (Table 2) . Although 325mg aspirin did not significantly increase closure time measured by PFA-100, 162mg aspirin significantly increased closure time in both diabetic and nondiabetic patients (p≤0.02 for both comparisons) (Table 3) .
Similarly, a significant decrease in rates of aspirin resistance was observed in both diabetic and non-diabetic patients with the administration of 162mg aspirin (p≤0.04 for both comparisons), however 325mg aspirin did not significantly affect rates of resistance compared to 81mg aspirin ( Figure 3 ). Similar rates of aspirin resistance were observed between patient groups at all aspirin doses (Figure 3 ).
Discussion
The current study was designed to compare the effect of aspirin dosing on platelet function in diabetic and nondiabetic patients from the ASPECT study, a randomized double blind double crossover trial employing multiple methods to assess aspirin responsiveness. During treatment with all aspirin doses there was no difference in platelet function or rates of aspirin resistance as measured by arachidonic acid-induced aggregation between diabetic and nondiabetic patients. However, during 81mg daily aspirin diabetic patients had higher platelet function compared to non-diabetic patients measured by VerifyNow, urinary 11-dehydro-thromboxane B 2 levels, and ADP-and collagen-induced LTA. Similarly, except for platelet aggregation measured by ADP-induced LTA and PFA-100, aspirin resistance was more common in diabetic patients compared to non-diabetic patients during 81mg aspirin therapy as measured by all other assays. In general, increasing the dose of aspirin in the diabetic patient above 81mg qd reduced platelet function and the prevalence of resistance to levels observed in the non-diabetic patient, suggesting that low dose aspirin therapy may not provide adequate platelet inhibition in selected diabetic patients and that higher aspirin dosing reduces the prevalence of outliers above the cutpoints for resistance.
These data agree with previous studies, where increased aspirin resistance and normal platelet function have been demonstrated in patients receiving low doses of aspirin (19, 20) . Lee et al demonstrated that 150mg and 300mg daily aspirin doses were associated with decreased rates of aspirin resistance compared to daily doses ≤100mg in patients with CAD measured by VerifyNow (19) . Moreover, Alberts et al demonstrated a significant portion of patients on low-dose aspirin therapy display normal platelet function measured by the PFA-100 (20) .
The exposure of collagen in the subendothelial matrix after endothelial disruption is an important primary activator of platelets that precedes thrombotic vessel occlusion. The observed
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dose-related effects of aspirin on collageninduced aggregation in diabetic patients, despite inhibition of COX-1 as measured by arachidonic acid-induced aggregation, suggests that aspirin may exert antiplatelet effects through non-COX-1 mediated pathways. Since collagen-induced aggregation was significantly higher in diabetic patients compared to non-diabetic patients during 81mg aspirin therapy, our data suggest that diabetic patients may require higher aspirin doses to achieve equivalent inhibition of collagen-induced aggregation.
Our data demonstrate that the diabetic patient's platelet response to ADP stimulation is unaffected by aspirin dose compared to the non-diabetic patient where we observed a lower prevalence of resistance at the higher dose. Recent studies have suggested an association between aspirin resistance and clopidogrel resistance in patients with diabetes, implying a global high platelet reactivity state in diabetic patients that can be detected by stimulation with multiple agonists (21) . In the current study, although AA-induced aggregation was equally suppressed in both patient groups, diabetic patients displayed greater ADPinduced aggregation at low and high doses compared to non-diabetic patients. These data suggest a potential mechanism to explain the benefit of dual antiplatelet therapy using an ADP receptor blocker in addition to aspirin in selected diabetic patients and may serve as important laboratory data for future studies of targeted antiplatelet therapy. Moreover, the reason for increased ischemic risk in the diabetic patient as compared to the non-diabetic as demonstrated in previous studies may in part be explained by higher global platelet reactivity (22) .
Finally, we demonstrated a dose dependent effect of aspirin on the formation of 11-dehydro-thromboxane B 2 in diabetic patients. A COX-2 source has been previously postulated as a mechanism to explain aspirin insensitive thromboxane production at low doses (23) . Our data provide support that higher doses of aspirin may significantly affect this source in diabetic patients.
Pretreatment studies could not be conducted since all patients had coronary artery disease and were therefore on aspirin therapy at the time of enrollment. In addition, since subjects were studied retrospectively, patient groups were not evenly distributed and comparisons between patients with type 1 and type 2 diabetes mellitus could not be performed due to the small sample size. However the Williams design is a robust method to determine treatment effects using small numbers of patients. Moreover, determination of diabetic status was assessed by clinical criteria rather than laboratory measurements of hemoglobin A1C. Thus, comparisons between the degree of glucose control and measurements of platelet function were not conducted. Future large-scale studies are needed to evaluate the clinical efficacy of higher aspirin dosing in diabetic patients in relation to glucose control.
In conclusion, diabetic patients with coronary artery disease during therapy with 81mg have a higher prevalence of aspirin resistance by selected tests, and greater ADP-and collagen-induced aggregation and in vivo production of thromboxane than non-diabetic patients. In general, increasing the dose of aspirin in the diabetic patient reduces platelet function and the prevalence of resistance to a level observed in the non-diabetic patient. The dose-related effects of aspirin on platelet function and thromboxane production in diabetic patients, despite near complete COX-1 blockade as determined by AA-induced aggregation, suggest that the antithrombotic properties of the drug may not all be explained by COX-1 inhibition. The observation that 
Legends Figure 1a . Graph demonstrating the prevalence of aspirin resistance (%) measured by VerifyNow in diabetic and non-diabetic patients at 3 doses of aspirin. +p ≤ 0.05 for difference between diabetic and non-diabetic patients treated with 81mg aspirin. Figure 1b . Graph demonstrating the prevalence of aspirin resistance (%) measured by urinary 11-dehydro-thromboxane B 2 levels in diabetic and non-diabetic patients at 3 doses of aspirin. +p≤0.05 for difference in resistance between diabetic and non-diabetic patients treated with 81mg aspirin. *p≤0.05 for difference in resistance between 81mg and 325mg aspirin.within the group of diabetic patients. Graph demonstrating the prevalence of aspirin resistance measured by 5µM ADPand 2µg/mL collagen-induced light transmittance aggregometry in diabetic and non-diabetic patients at 3 doses of aspirin. +p≤0.05 for difference in resistance measured by 5µM ADP-induced light transmittance aggregometry between diabetic and non-diabetic patients treated with 325mg aspirin. *p≤0.05 for difference in aspirin resistance between 81 mg and 325 mg aspirin measured by 5µM ADP-induced light transmittance aggregometry in the nondiabetic patient group. ++p≤0.05 for difference in resistance measured by 2µg/mL collagen-induced light transmittance aggregometry between diabetic and non-diabetic patients treated with 81mg aspirin. Ŧp≤0.05 for difference in resistance between 81mg and 162 mg; and 81 mg and 325 mg; as measured by 2µg/mL collagen-induced light transmittance aggregometry in the diabetic group. Graph demonstrating the prevalence of aspirin resistance measured by PFA-100 in diabetic and non-diabetic patients at 3 doses of aspirin. *p≤0.05 for difference between 81 mg and 162 mg in the diabetic and non-diabetic groups.
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